Tag Archives: Jason Mccarthy
Hancock Jaffe Laboratories (HJLI) Receives a Buy from Maxim Group
Maxim Group analyst Jason McCarthy maintained a Buy rating on Hancock Jaffe Laboratories (HJLI – Research Report) yesterday and set a price target of $3.00. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.38.
Maxim Group Keeps Their Buy Rating on Biocept (BIOC)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Biocept (BIOC – Research Report) yesterday and set a price target of $1.00. The company’s shares closed last Monday at $0.37, close to its 52-week low of $0.23. According to
Maxim Group Remains a Buy on ContraFect (CFRX)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ContraFect (CFRX – Research Report), with a price target of $2.00. The company’s shares closed last Monday at $0.40, close to its 52-week low of
Maxim Group Remains a Buy on BeiGene (BGNE)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BeiGene (BGNE – Research Report), with a price target of $210.00. The company’s shares closed last Monday at $161.08. According to TipRanks.com, McCarthy ‘s ranking
Maxim Group Keeps a Buy Rating on Actinium Pharmaceuticals (ATNM)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) yesterday and set a price target of $1.50. The company’s shares closed last Monday at $0.22, close to its 52-week low of $0.19. According
Maxim Group Keeps a Buy Rating on BeiGene (BGNE)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BeiGene (BGNE – Research Report), with a price target of $210.00. The company’s shares closed last Monday at $182.55. According to TipRanks.com, McCarthy has 0
